When adding SGLT2 inhibitors, the risks were reduced to 8% (IQR, 4.5%–13.4%) for all-cause death and 9.7% (IQR, 7.7%–12.3%) for hospitalization for heart failure in the first cycle. The gene discussed is SLC5A2; the disease is heart failure.